Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human GLP1R Antikörper:
anti-Mouse (Murine) GLP1R Antikörper:
anti-Rat (Rattus) GLP1R Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal GLP1R Primary Antibody für DB, ICC - ABIN4314326
Kedees, Guz, Grigoryan, Teitelman: Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor. in Peptides 2013
Show all 6 Pubmed References
Human Polyclonal GLP1R Primary Antibody für IF (p), IHC (p) - ABIN731333
Zhou, Yang, Xin, Li, Guo, Hu, Zhou, Zhang, Zhang, Han, Chen: Exendin-4 protects adipose-derived mesenchymal stem cells from apoptosis induced by hydrogen peroxide through the PI3K/Akt-Sfrp2 pathways. in Free radical biology & medicine 2014
Show all 2 Pubmed References
Human Polyclonal GLP1R Primary Antibody für IHC, IHC (p) - ABIN270557
Matveyenko, Dry, Cox, Moshtaghian, Gurlo, Galasso, Butler, Butler: Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. in Diabetes 2009
Show all 2 Pubmed References
Human Monoclonal GLP1R Primary Antibody für CyTOF, FACS - ABIN4899829
Thompson, Stephens, Bain, Kanamarlapudi: Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation. in PLoS ONE 2016
Role of cysteine 341 and arginine 348 of GLP-1 receptor in G-protein coupling.
cryo-electron microscopy structure of the peptide-activated GLP-1R-Gs complex at near atomic resolution
crystal structure of the full-length GLP-1 receptor bound to a truncated peptide agonist
crystal structures of the human GLP-1R transmembrane domain in complex with two different negative allosteric modulators, PF-06372222 and NNC0640, at 2.7 and 3.0 A resolution, respectively
Data suggest that pancreatic level of GLP1R is highest in insulin (zeige INS Antikörper)-secreting cells; here, highest intensity of GLP1R immunostaining was observed in beta-cells in pancreatic tissues obtained from organ-donor cadavers with type 2 diabetes.
Data show that purified glucagon-like peptide-1 (GLP-1 (zeige GCG Antikörper)) receptor (GLP1R)GLP1R in nanodiscs that could bind to GLP-1 (zeige GCG Antikörper) and exendin-4 and activate Gs protein.
Dapagliflozin, when added in real life to patients with T2DM treated with GLP1-R agonists, induced a further significant, albeit modest improvement in A1C and a further weight loss.
analysis of the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor
GLP1-R may represent a novel target for treating bronchial hyperresponsiveness.
Our studies show that GLP-1R is widely expressed throughout the human hypothalamus. The decreased expression of GLP-1R in the PVN and IFN of T2DM patients may be related to the dysregulation of feeding behavior and glucose homeostasis in type 2 diabetes mellitus.
The effects of GLP-1 (zeige GCG Antikörper)-based therapies on blood glucose in type 2 diabetics are not mediated through microvascular responses.
In conclusion, exenatide significantly improves coronary endothelial function in patients with newly diagnosed type 2 diabetes. The effect may be mediated through activation of AMPK (zeige PRKAA1 Antikörper)/PI3K (zeige PIK3CA Antikörper)-Akt (zeige AKT1 Antikörper)/eNOS (zeige NOS3 Antikörper) pathway via a GLP-1R/cAMP-dependent mechanism.
GLP-1R is highly expressed within the lateral septum.
Study showe that GLP (zeige GOLGA6A Antikörper)-producing fibers interact with hypothalamic arcuate nucleus (ARC (zeige NOL3 Antikörper)) Kiss1 (zeige KISS1 Antikörper) cells that express GLP-1R, and GLP-1R signaling directly activates ARC (zeige NOL3 Antikörper) Kiss1 (zeige KISS1 Antikörper) function in an estradiol-independent manner. Pharmacological activation of GLP-1R signaling during fasting or pharmacological inhibition of CNS GLP-1R signaling during normal feeding does not alter circulating luteinizing hormone levels.
The increased calcium response mediated by secretin (zeige SECR Antikörper) in the absence of GLP-1R was paralleled by an increased glucose-dependent insulin (zeige INS Antikörper) response, indicating that the heterodimeric receptor complexes modulate secretin (zeige SECR Antikörper) responses.
Menin and PRMT5 (zeige PRMT5 Antikörper) suppress GLP1R transcript levels and PKA-mediated phosphorylation of FOXO1 (zeige FOXO1 Antikörper) and CREB (zeige CREB1 Antikörper).
Glp1r knockdown reduced anxiety-like behavior, implicating paraventricular nucleus GLP-1 (zeige GCG Antikörper) signaling in behavioral stress reactivity
Enhanced beta-cell GLP-1R signaling contributes to improved glucose regulation after vertical sleeve gastrectomy by promoting increased glucose-stimulated insulin (zeige INS Antikörper) secretion.
Results suggest a detectable but only modest role for GLP-1R signaling in mediating the effects of Roux-en-Y gastric bypass and that this role is limited to its well-described action on glucose regulation.
Hypothalamic Glp1r is sufficient but not necessary for regulation of energy balance and glucose homeostasis.
Genetic deletion of both GLP-1 (zeige GCG Antikörper) and GIP (zeige GIP Antikörper) receptors reveals that they are required to maintain an adequate islet number in adulthood and to maintain normal beta cell responses to glucose.
present study provides critical insights regarding the nature by which GLP-1 (zeige GCG Antikörper) signaling controls reinforced behaviors and underscores the importance of both peripheral and central GLP-1R signaling for the regulation of addictive disorders.
induces insulin secretion\; mediates neuroendocrine signaling of feeding behavior\; mediates cardiovascular response and increased blood pressure
glucagon-like peptide 1 receptor
, glucagon-like peptide 1 receptor-like
, GLP-1 receptor
, pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1